The antiarrhythmic efficacy of the invastigational class Ic-drug nicainoprot (N.) was evaluated in 61 patients with frequant premature ventdcular beats (PVBs) in a doubleblind, cross*over trial including four 4-day bedods with administration of placebo (PL) or N. in doses of 200, 400, 600 mg t.i.d, in randomized order. Total PVBs/24 h were significantly reduced by 400 mg N. (65 %) and 600 mg N. t.i.d. (71%). Individual therapeutic response, defined as a reduction of total PVBs > 75 %, of vantricular pairs > 90 % and elimination of ventricular runs, was found in 6 (10 %), 10(16%),21 (34 %), and 22 (36 %) patients with PL, 200 mg N., 400 mg N. and 600 mg N., respectively. Heart rate, mean blood pressure, QT and JTc intervals were not significantly influenced by any doze of N. There was a positive correlation batv~an mean plasma concentrations of N. and a mild prolongation of the PR interval. Extracardiac side effects (nausea, dizziness, gamrointastinal discomfort, exanthema) in 7 % of the patients occured mainly after 600 mg N. t.i.d. In one patient fatal ventriculer fibrillation occurred during the first treatment period (600 rng ti.d.). It is concluded that nioainoprol leads to a dose-related suppression of PVBs in patients with ventricular arrhythmias due to various cardiac disorders. With regard to both antiarrhythmic efficacy and possible adverse effects a dose of 400 mg t.i.d. appears recommendable. This dose covered more than 90 % of the responding patients with virtually no side effects. In 114 patients (p) with clinically documented sustained ventricular tachyarrhythmias (VTA), programmed electrical stimulation (PES) was used to identify antiarrhythmic drugs (AAD) for effective suppression of inducible VTA that were elecited by up to 3 ventricular extrastimuli without AAD. Sotalol (S) was administered at 1.5 mg/kg i.v.. By intraindividual comparison, S was the most frequently effective agent and suppressed inducibility in 52% of the p. Quinidine had a success rate of 36%, propafenon of 28%, other class I agents were even less effective. After failure of conventional drugs, amiodarone suppressed inducibility only in 5/36 p in whom S had been ineffective. To demonstrate the long-term predictive value of PES, 53 S-responders were followed for a mean of 29 months at doses of 360 + 80 mg]d S. Five p suffered from recurrences of VTA and two p died suddenly. Minor side effects occurred in four p.
In 114 patients (p) with clinically documented sustained ventricular tachyarrhythmias (VTA), programmed electrical stimulation (PES) was used to identify antiarrhythmic drugs (AAD) for effective suppression of inducible VTA that were elecited by up to 3 ventricular extrastimuli without AAD. Sotalol (S) was administered at 1.5 mg/kg i.v.. By intraindividual comparison, S was the most frequently effective agent and suppressed inducibility in 52% of the p. Quinidine had a success rate of 36%, propafenon of 28%, other class I agents were even less effective. After failure of conventional drugs, amiodarone suppressed inducibility only in 5/36 p in whom S had been ineffective. To demonstrate the long-term predictive value of PES, 53 S-responders were followed for a mean of 29 months at doses of 360 + 80 mg]d S. Five p suffered from recurrences of VTA and two p died suddenly. Minor side effects occurred in four p.
Conclusion: Sotalol appears to be an effective agent for acute and chronic therapy of malignant ventricular tachyarrhythmias when individually optimized by programmed electrical stimulation. After failure of sotalol, suppression of inducibility of ventricular tachyarrhythmias appears to be rarely impaired by amiodarone. Both conduction time (CT) and effective refractory period (ERP), absolute and relative to action potential duration (APD), are major determinants of re-entry arrhythmia circuits. We compared the effects of disopyramide, mcxiletine, aprindine and flecainide on APD, ERP, ERP/APD and intraventricular CT in 30 patients at different pacing cycle length (6110 msec, 350 msec). A modified contact electrode technique was used to measure both APD and ERP at the same ventricular site. CT was measured from the stimulus artifact (applied to RV) to the end of ORS. Results (percent change VS baseline; *P < 0.05 VS baseline, BCL; basic cycle length)
Non-sustained VT was induced in two patients after flecainide. These results demonstrate that effects of antiarrhythmic drugs on membrane excitability and conduction properties can be differentiated in human. This may be important for a more rational approach to antiarrhythmic therapy and also proarrhythmic effects.
ANTIAERHYTHMIC EFFECTS OF CAEVEDILOL, A NEW BETA-BLOCKER WITH VASODILATING PROPERTIES
A. Lahiri C. Kinsey, P. DasGupta, B. Muller-Beckman, and R. Vanderdoes, Norhtwick Park Hospital, Harrow, UK Carvedilol (C) is a new non-selectlve beta blocker with alpha mediated vasodilatln E properties.
C has been shown to be effective in hypertension (HT)) stable angina (SA) and congestive heart failure (CHF).
We have studied the effects of C on ventricular premature beats (PVC) in 65 patients (pts) undergoln 8 treatment with C (12.5 -50 mg bid) for 4-8 weeks.
12 pts had HT, 41 had SA and 12 had CHF.
Holter monitorln E for 24 hrs was performed before and after active C therapy.
Median PVC count decreased from 25.5 to 6.0, p<O.001, n=52.
Reduction in PVC activity oecured in 77%; 23% of the pts with multlfocal PVC changed the morphology to unifocal. Nonsustained ventrlcular tachTcardia (VT) was present in 4 before treatment and abolished in all. R on T PVC was present in 6: it decreased in 5 and increased in i.
New VT (<8 beats) occurred in 2 pts but QT-prolongatlon was not noted.
Carvedilol does not appear to possess proarrhythmla effects and chronic therapy reduces PVC activity in a wide range of pts, this property of C is complimentary to its hypotenslve and anti-lschemlc effects.
C l a s s III M o d e of A c t i o n of H 2 3 4 / 0 9 -A D o u b l e -b l i n d , C r o s s -o v e r , S t u d y U s i n g T r a n s o e s o p h a g e a l
Atrial S t i m u l a t i o n in H e a l t h y V o l u n t e e r s . B.DarpS, O.Almgren, R.Bergstrand, C.Gotffridsson, B.Sandstsdt, N.Edvardason, Div of Cardiology, Sahlgren's University Hospital, GSteborg, Sweden.
H234/09 is a new agent with class III mode of action. In this double blind, cross-over study, 12.8 nmoi (4.5 mg) of H234/09 was infused intravenously over 10 rain in 9 healthy male volunteers.Transoesophageal atrial stimulation (TAS) was used to standardize the heart rate. The QTend (QTs) and the QT top (QTt) was measured during atrial pacing at a basic cycle interval of 500 and 600 ms before and at 0, 60, 90 and 300 rain after end of infusion. We conclude that H234/09 significantly increased the QT interval by 10 to 14%, showing the maximal change at the very end of the repoladzation (QTe). TAS was a reliable method to achieve heart rate control.
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CLINICAL ELECTROPHYSIOLOGIC EFFECT OF UK 68,798. The effect of UK68,798 (UK68), a new class III anti-arrhythmic agent on the clinical electrophysiologic parameters were studied in 12 patients with supraventricular arrhythmias (age 39+17 y), before and during 45-55 min of continuous infusion of UK68 (10 ug/kg/60 min (6 patients) or 4 ug/kg/15 min followed by 2 ug/Kg/45 min (6 patients)). UK68 had no effect on the RR, AH, HV intervals or QRS duration, but prolonged the QTc interval significantly (* p<0.05) (420_+40 to 454+40 ms*). Right ventricular monophasic action potential duration (MAP) prolonged significantly during sinus rhythm (238_+16 to 283_+24 ms*). During fixed ventricular pacing (at 400 ms), QT and MAP intervals increased by 12_+7% and 19_+6% respectively. There were increases in the atrial effective refractory period (ERP) (204+30 to 249+29 ms*) and functional refractory period (FRP) (238___36 to 284-_+36 ms *). Also the ventricular refractoriness increased (ERP:195_+17 to 221+23 ms*; FRP:230+20 to 262 _+22 ms*) while the ratios of V-~IAP/V-ERP and V--MAP/V-FRP remained the same before and during infusion (1.1_+0.1%). Conclusion UK68 has unique class III effect. It 1) homogenously prolongs RP and MAP and 2) has a selective effect on atria and ventricles.
